Kooth Share Discussion Threads

[c3479z1] 16/3/2023 12:47:47

imagine that any California contract would require recruitment drive for local psychologists/psychiatrists, so would need a lot of management time at least initially and high initial costs incurred. Potential thereafter is admittedly enormous if they can pull it off.

[babbler] 16/3/2023 12:07:28

You want to lose your profit?

[natty27] 16/3/2023 10:45:52

Nice trade from bell, profits gone straight into CLON ;)

[rimau1] 16/3/2023 09:46:49

I always valued us on ARR, a prudent 3x ARR should be the minimum. So the UK is worth £60m and for me the US you can add on another £20m of ARR so my valuation of Kooth is £120m if Pen migrates to a full programme.

[rimau1] 16/3/2023 09:09:02

They did the work for you in the rns 74tom - 6m population in the contract category of 13-25 year olds. I think Kooth in 2024 will be double the size that the business is today.

[rimau1] 16/3/2023 08:30:40

This was way beyond my 2023 expectations!!! The US opportunity is mind boggling. California could be as large a contract as the UK business, cautioning that we meed to see numbers. Just need confirmation later this year that the Pen pilot expands and we have results in April to add some meat to the bones.

[sebass] 24/1/2023 11:17:51

I think there has beeen a recent change in legislation which eliminates the requirement for clinician and patient to be registered in the same state. Might make it easier for Kooth to expand in States


Telehealth access legislation

[c3479z] 23/1/2023 09:46:18

pricey based on mkt cap vs profitability, though they are in the build phase, cash flow, cash on hand 8m though they say enough to reach operating cash positivity. on the other hand, their mkt position is excellent and some opportunity to enhance by picking up unlisted competitors with restricted access to cash.

[rimau1] 23/1/2023 08:40:06

Ok not a chat bot. All opinions welcome i just get a little frustrated with throw away one liners such as “it seems a bit pricey” can you not do a few mins research to back it up or qualify it?Different opinions are invaluable if you can offer some quality insight but “constrained nhs budget” really doesn’t count. Pricey based on what, forecasts, ARR, earnings, based on competitors valuations, the cost of eggs?

[c3479z] 23/1/2023 07:36:48

only expressing an opinion, differing opinions make a market after all,
you're entitled to your view, rimau1, suspect you are better acquainted with the company,
my opinion shared by investor's champion comment if you care to look at it,

[rimau1] 22/1/2023 22:46:46

c3479z you are clearly a chat bot

[c3479z] 22/1/2023 22:23:06

seems a bit pricey, nevertheless, unless growth is rapid from here on in, which is a tough ask given the constrained NHS budget.

[rimau1] 22/1/2023 21:41:45

Therapists costing 3x more is solved simply by Koo charging 3x more FFS!!!! Koo also set up a local US mgt team it won’t be managed from the UK. Do you have any sensible questions?

[c3479z] 22/1/2023 18:13:51

seems a bit pricey unless they can profitably scale-up in the States, problem there is the therapists cost 3x the UK rate- are the therapists under contract only to Kooth and do not work anywhere else at all? Must therefore adopt a different model for the US and difficult to manage it from the UK for such a small company.

[rimau1] 22/1/2023 14:38:12

Last post from me here for a while. They appear (understandably given Kooth UK performance track record) very confident that the Penn pilot will be successful and lead to a larger longer contract which will in turn lead to further state contracts. However practitioners need to be licensed in the state that they operate in so it seems to me Koo will expand state by state rather than multi state roll outs which helps keep a lid on costs and retains focus but obviously takes longer. In terms of ex UK ex US expansion KOO will licence their technology out which is an excellent strategy IMO. Bolt on acquisitions unlikely although they are constantly being approached especially by distressed assets but the KOO model is primarily organic. The other snippet was that the existing cash runway extends for 2 years but in any case they expect to be cash flow positive within 3-6 months. Exciting times.

[rimau1] 19/1/2023 15:55:54

Excellent presentation this afternoon, the size of the prize in the US is mind boggling. $6bn of US state funding announced in 2022 alone and the US youth market is expected to be worth $26bn by 2027.

[rimau1] 19/1/2023 08:17:56

Excellent update. Very below the radar and the significant derating last year was simply due to the growth/tech stock association and unwarranted IMO. KOO are trading on 2 x historic ARR after stripping out net cash which is simply too cheap with sufficient balance sheet strength to find expansion plans. Plenty of clues in this update that the business is doing well; entrenched in the NHS, rolling out in Scotland, interestingly now providing an A&E emergency response to alleviate pressure on A&E and most importantly the US rollout which is historically the amber flag for me (as few businesses succeed in entry)is progressing well. Penn is bedding in and should result in further contract awards. Patience required but this is a high conviction long term hold for me.